Clinical Trial Update: Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line gemcitabine hydrochloride, cisplatin, and sunitinib malate for locally advanced or metastatic transitional cell carcinoma of…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Urothelium

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine hydrochloride (Gemcitabine hydrochloride)
• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: Cardiff University | Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Status: COMPLETED